ClinicalTrials.gg
Status unknownNCT03456609Updated Mar 7, 2018

Shenqi Fuzheng Injection for the Treatment of Cancer-related Fatigue in Patients(BCS) With Digestive Tract .

An interventional study of shenqifuzheng injection and Sodium Chloride Injection 0.9% in Carcinogenic Fatigue, sponsored by Livzon Pharmaceutical Group Inc.. Status unknown at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-03-07.

Sponsored by Livzon Pharmaceutical Group Inc. (part of Joincare Pharmaceutical Group Industry Co., Ltd.) · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2017), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 38 studies in Fatigue with a site in China — 10 open to participants now, 11 under way, 2 of them phase 3. Fatigue · China.

Planned enrollment
23rd of 33
60 · median 90
Started
2018
the only one that year
No phase
24 of 38
4 open now
Registered
3rd of 38
by date

Among the 38 studies in Fatigue with a site in China, this one is the 23rd largest by planned enrollment of the 33 interventional ones that give a count, is the only one that started in 2018, is one of 24 with no phase, and was the 3rd registered.

Fatigue

2,233 studies on the registry are indexed under Fatigue; 429 are open to participants now.

Browse Fatigue studies →

Open to participants now

10 of the 38 studies in Fatigue with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 241 Fatigue studies recruiting now, 112 (46%) set no upper age limit and 99 (41%) stop at 75 or younger; 23 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Fatigue with a site in China, or all of them as a file.
02

Study summary

The efficacy and safety of cancer patients in patients with gastrointestinal cancer (Palliative care) in patients with gastrointestinal tumor (chemotherapy) were prospectively, randomized blind, multicenter clinical trials. They were randomly divided into 2 groups, test group Shenqifuzheng injection of 500 ml, the control group 0.9% sodium chloride injection, 500 ml, intravenous drip, 1 times a day, 14 days post, rest is 7 days, 21 days each for a period of treatment, observation of two procedures. At the same time, according to the NCCN guide and the health ministry issued the diagnosis and treatment guidelines for cancer treatment. The main curative effect of the clinic was to evaluate the pretreatment of cancer due to the fatigue score of the patients before and after treatment -- the Piper fatigue revision scale was used to evaluate the Chinese version. Assess effectiveness and safety based on clinical assessment

Read the detailed description

Factors for the purpose of this study by observing theShenqifuzheng injection before and after treatment in patients with carcinoma due to fatigue scale scores, the classification of syndromes, the quality of life score changes and related laboratory index, evaluation factors ginseng and astragalus injection on the digestive tract tumor (chemotherapy) in patients with cancer-related fatigue and quality of life improved efficacy and safety. The experimental group was randomly divided into 2 groups, experimental group Shenqifuzheng injection of 500 ml. The control group was 0.9% sodium chloride injection, 500ml, intravenous drip, 1 time daily, 14 days for continuous use, 7 days of rest, and 1 treatment for each 21 days, and 2 courses were observed. At the same time, according to the NCCN guide and the health ministry issued the diagnosis and treatment guidelines for cancer treatment.

Main efficacy evaluation indexes before and after treatment for cancer-related fatigue rating - adopting the Piper fatigue scale revised Chinese version, compare the experimental group and the control group before and after treatment cancer-related fatigue rating difference have differences. Secondary efficacy evaluation index to compare the ECOG score difference before and after the treatment, the quality of life score difference before and after the treatment, TCM syndrome curative effect, single symptom curative effect of immune function, tumors had curative effect (if any) and chemotherapy completion. Safety assessment includes the observation of vital signs, blood routine, urinary routine, routine stool, liver function, renal function, electrocardiogram examination, and adverse reactions during the treatment.

03

Conditions studied

  • Carcinogenic Fatigue

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Patients with gastric cancer, esophageal cancer or colorectal cancer diagnosed by pathology or cytology;
    1. Diagnostic criteria for cancer-related fatigue;
    1. Syndrome differentiation of Chinese medicine is a syndrome of lung temper;
    1. Estimated survival over 3 months;
    1. score is less than or equal to 3
    1. Age 18 \~ 80 years old;
    1. Non-surgical indications or reluctance to operate the surgical treatment;
    1. 70 g/L or higher HGB;
    1. Stop and chemotherapy for more than 1 month;
    1. The patient is willing to accept the treatment of the programme, and can follow the doctor's advice to take the medicine and comply with the patient.

Exclusion criteria

Exclusion Criteria:

    1. Any situation that may hinder the subject from completing the clinical trial, including but not limited to serious, uncontrollable organic disease or infection:

      1. cardiovascular diseases, such as heart failure ( III-IV), uncontrolled coronary heart disease, cardiomyopathy, arrhythmia, etc.
      2. serious clinical infection of activity (greater than 3 degrees nci-ctcae 4.03)
      3. uncontrolled hypertension (systolic pressure is greater than 160 mmHg or diastolic pressure is greater than 100 mmHg, despite the best drug treatment);
      4. severe liver and kidney function abnormality (blood creatinine is greater than 1.5 times ; or AST is greater than 5 times ULN; is greater than 1.5 times ULN.
      5. other diseases that need to be controlled: pulmonary congestion, etc.
    1. Patients with symptoms, uncontrollable nerves, mental illness or mental disorders;
    1. Compliance.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    shenqifuzheng

    Drug: shenqifuzheng injection

  • Placebo comparator
    0.9%sodium chloride

    Drug: Sodium Chloride Injection 0.9%

Interventions

  • Drugshenqifuzheng injection

    500ml shenqifuzheng daily(at day 1-14 and day22-36)through intravenous infusion.

  • DrugSodium Chloride Injection 0.9%

    500ml sodium chloride(0.9%)daily(at day 1-14 and day22-36)through intravenous infusion.

06

What researchers measure

Primary outcomes

  1. Piper Fatigue Scale(PFS)

    Change From Baseline in Piper Fatigue Scores at 42 days

    Time frame: 42 days

07

Study locations

1 of 1 sites recruiting
  • First affiliated hospital of guangzhou university of traditional Chinese medicine
    Guangzhou, Guangdong, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2018 (actual). Primary completion is estimated for Dec 2019, 23 months after the start.

Of 53 industry-sponsored interventional studies with no phase under Fatigue, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's planned 23 months is above that.

Counting every sponsor, half of 990 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2017
First posted
Mar 7, 2018
StartActual
Jan 18, 2018
Primary completionEst.
Dec 30, 2019
CompletionEst.
Dec 30, 2019
Last update
Mar 7, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03456609
Responsible party
Sponsor
First posted
Mar 7, 2018
Start date
Jan 18, 2018
Primary completion
Dec 30, 2019 (estimated)
Completion
Dec 30, 2019 (estimated)
Last update
Mar 7, 2018

Study contacts

lin lizhu, Dr.
Contact
13501505588@139.com
13501505588
lin lizhu, Dr.
principal investigator · First affiliated hospital of guangzhou university of traditional Chinese medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion